| Literature DB >> 29426830 |
Alisha Pandit1,2, Houry Leblebjian3, Sarah P Hammond1,2,4, Jacob P Laubach1,4, Paul G Richardson1,4, Lindsey R Baden1,2,4, Francisco M Marty1,2,4, Nicolas C Issa5,6,7.
Abstract
Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma patients on maintenance lenalidomide or bortezomib following autologous HCT. One hundred thirty-seven multiple myeloma patients on maintenance lenalidomide or bortezomib post-auto-HCT who received either MMR or herpes zoster vaccine were analyzed and any adverse events documented in the medical record in the 42 days following vaccination were recorded. Patients were vaccinated a median of 25 months (range, 18-62) post transplant. The most common post-vaccination adverse event was upper respiratory tract infection (18/137 patients); no rash attributed to vaccine strains or other adverse outcomes potentially related to the vaccines were identified. MMR and herpes zoster vaccination were safe and well-tolerated in this cohort.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29426830 DOI： 10.1038/s41409-018-0112-x
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483